Pyxis Oncology, Inc. Increase (Decrease) in Accounts Payable
Pyxis Oncology, Inc. (PYXS) reported Increase (Decrease) in Accounts Payable of -$7.62 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-13
- Pyxis Oncology, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$1.72M, a 126.20% decline year-over-year.
- Pyxis Oncology, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$5.90M.
- Pyxis Oncology, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $1.13M.
- Pyxis Oncology, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $344.00K.
- Pyxis Oncology, Inc. increase (decrease) in accounts payable for fiscal 2025 was $6.03M, a 402.17% increase from fiscal 2024.
- Pyxis Oncology, Inc. increase (decrease) in accounts payable for fiscal 2024 was $1.20M.
- Pyxis Oncology, Inc. increase (decrease) in accounts payable for fiscal 2023 was -$3.51M.
- Pyxis Oncology, Inc. increase (decrease) in accounts payable for fiscal 2022 was -$8.33M, a 279.37% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$7.62M 10-Q · filed 2026-08-13 | -$6.49M derived: sum of 3 quarters · filed 2026-08-13 | -$6.14M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$5.90M 10-Q · filed 2026-05-14 | -$4.77M derived: sum of 2 quarters · filed 2026-05-14 | -$4.42M derived: sum of 3 quarters · filed 2026-05-14 | $2.14M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $1.47M derived: sum of 2 quarters · filed 2026-03-23 | $8.04M derived: sum of 3 quarters · filed 2026-08-13 | $6.03M 10-K · filed 2026-03-23 |
| 2025-09-30 | $344.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $6.91M derived: sum of 2 quarters · filed 2026-08-13 | $4.90M 10-Q · filed 2025-11-03 | $4.89M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $6.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $4.55M 10-Q · filed 2026-08-13 | $4.54M derived: sum of 3 quarters · filed 2026-08-13 | $3.94M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$2.01M 10-Q · filed 2026-05-14 | -$2.02M derived: sum of 2 quarters · filed 2026-05-14 | -$2.63M derived: sum of 3 quarters · filed 2026-05-14 | $552.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$612.00K derived: sum of 2 quarters · filed 2026-03-23 | $2.56M derived: sum of 3 quarters · filed 2026-03-23 | $1.20M 10-K · filed 2026-03-23 |
| 2024-09-30 | -$602.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $2.58M derived: sum of 2 quarters · filed 2025-11-03 | $1.21M 10-Q · filed 2025-11-03 | $1.56M derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | $3.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $1.81M 10-Q · filed 2025-08-14 | $2.16M derived: sum of 3 quarters · filed 2025-08-14 | $618.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$1.36M 10-Q · filed 2025-05-15 | -$1.01M derived: sum of 2 quarters · filed 2025-05-15 | -$2.56M derived: sum of 3 quarters · filed 2025-05-15 | -$4.12M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $350.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | -$1.19M derived: sum of 2 quarters · filed 2025-03-18 | -$2.75M derived: sum of 3 quarters · filed 2025-03-18 | -$3.51M 10-K · filed 2025-03-18 |
| 2023-09-30 | -$1.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$3.10M derived: sum of 2 quarters · filed 2024-11-12 | -$3.86M 10-Q · filed 2024-11-12 | -$5.74M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$1.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$2.31M 10-Q · filed 2024-08-14 | -$4.20M derived: sum of 3 quarters · filed 2024-08-14 | -$6.51M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$753.00K 10-Q · filed 2024-05-14 | -$2.64M derived: sum of 2 quarters · filed 2024-05-14 | -$4.95M derived: sum of 3 quarters · filed 2024-05-14 | $815.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$1.89M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$4.20M derived: sum of 2 quarters · filed 2024-03-21 | $1.57M derived: sum of 3 quarters · filed 2024-03-21 | -$8.33M 10-K · filed 2024-03-21 |
| 2022-09-30 | -$2.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $3.45M derived: sum of 2 quarters · filed 2023-11-07 | -$6.44M 10-Q · filed 2023-11-07 | -$2.41M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $5.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | -$4.13M 10-Q · filed 2023-08-11 | -$98.00K derived: sum of 3 quarters · filed 2023-08-11 | $876.00K derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | -$9.90M 10-Q · filed 2023-05-11 | -$5.86M derived: sum of 2 quarters · filed 2023-05-11 | -$4.89M derived: sum of 3 quarters · filed 2023-05-11 | -$4.81M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $4.03M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $5.01M derived: sum of 2 quarters · filed 2023-03-22 | $5.09M derived: sum of 3 quarters · filed 2023-03-22 | $4.64M 10-K · filed 2023-03-22 |
| 2021-09-30 | $974.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $1.06M derived: sum of 2 quarters · filed 2022-11-01 | $610.00K 10-Q · filed 2022-11-01 | $1.05M derived: sum of 4 quarters · filed 2022-11-01 |
| 2021-06-30 | $83.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$364.00K 10-Q · filed 2022-08-15 | $77.00K derived: sum of 3 quarters · filed 2022-08-15 | |
| 2021-03-31 | -$447.00K 10-Q · filed 2022-05-13 | -$6.00K derived: sum of 2 quarters · filed 2022-05-13 | ||
| 2020-12-31 | $441.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $558.00K 10-K · filed 2022-03-29 | ||
| 2020-09-30 | $117.00K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |